206 related articles for article (PubMed ID: 24479494)
1. HMGB1 as a therapeutic target for sepsis: it's all in the timing!
Gentile LF; Moldawer LL
Expert Opin Ther Targets; 2014 Mar; 18(3):243-5. PubMed ID: 24479494
[TBL] [Abstract][Full Text] [Related]
2. Targeting HMGB1 in the treatment of sepsis.
Wang H; Ward MF; Sama AE
Expert Opin Ther Targets; 2014 Mar; 18(3):257-68. PubMed ID: 24392842
[TBL] [Abstract][Full Text] [Related]
3. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.
Wang H; Ward MF; Sama AE
Shock; 2009 Oct; 32(4):348-57. PubMed ID: 19333143
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of HMGB1-targeting agents in sepsis.
Wang H; Zhu S; Zhou R; Li W; Sama AE
Expert Rev Mol Med; 2008 Nov; 10():e32. PubMed ID: 18980707
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes.
Stevens NE; Chapman MJ; Fraser CK; Kuchel TR; Hayball JD; Diener KR
Sci Rep; 2017 Jul; 7(1):5850. PubMed ID: 28724977
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane Reduces HMGB1-Mediated Septic Responses and Improves Survival Rate in Septic Mice.
Lee IC; Kim DY; Bae JS
Am J Chin Med; 2017; 45(6):1253-1271. PubMed ID: 28830206
[TBL] [Abstract][Full Text] [Related]
7. Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.
Tamada K; Nakajima S; Ogawa N; Inada M; Shibasaki H; Sato A; Takasawa R; Yoshimori A; Suzuki Y; Watanabe N; Oyama T; Abe H; Inoue S; Abe T; Yokomizo T; Tanuma S
Biochem Biophys Res Commun; 2019 Apr; 511(3):665-670. PubMed ID: 30826057
[TBL] [Abstract][Full Text] [Related]
8. JH-4 reduces HMGB1-mediated septic responses and improves survival rate in septic mice.
Lee W; Yuseok O; Yang S; Lee BS; Lee JH; Park EK; Baek MC; Song GY; Bae JS
J Cell Biochem; 2019 Apr; 120(4):6277-6289. PubMed ID: 30378167
[TBL] [Abstract][Full Text] [Related]
9. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock.
Sundén-Cullberg J; Norrby-Teglund A; Rouhiainen A; Rauvala H; Herman G; Tracey KJ; Lee ML; Andersson J; Tokics L; Treutiger CJ
Crit Care Med; 2005 Mar; 33(3):564-73. PubMed ID: 15753748
[TBL] [Abstract][Full Text] [Related]
10. High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
Czura CJ; Yang H; Tracey KJ
J Infect Dis; 2003 Jun; 187 Suppl 2():S391-6. PubMed ID: 12792856
[TBL] [Abstract][Full Text] [Related]
11. Zingerone reduces HMGB1-mediated septic responses and improves survival in septic mice.
Lee W; Ku SK; Bae JS
Toxicol Appl Pharmacol; 2017 Aug; 329():202-211. PubMed ID: 28610995
[TBL] [Abstract][Full Text] [Related]
12. Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
Bae JS
Arch Pharm Res; 2012 Sep; 35(9):1511-23. PubMed ID: 23054707
[TBL] [Abstract][Full Text] [Related]
13. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Sama AE; D'Amore J; Ward MF; Chen G; Wang H
Acad Emerg Med; 2004 Aug; 11(8):867-73. PubMed ID: 15289194
[TBL] [Abstract][Full Text] [Related]
14. Aloin Reduces HMGB1-Mediated Septic Responses and Improves Survival in Septic Mice by Activation of the SIRT1 and PI3K/Nrf2/HO-1 Signaling Axis.
Yang S; Lee W; Lee BS; Lee C; Park EK; Ku SK; Bae JS
Am J Chin Med; 2019; 47(3):613-633. PubMed ID: 30966773
[TBL] [Abstract][Full Text] [Related]
15. Ameliorative effect of a rarely occurring C-methylrotenoid on HMGB1-induced septic responses in vitro and in vivo.
Yang EJ; Lee W; Song KS; Bae JS
Biochem Pharmacol; 2016 Jun; 110-111():58-70. PubMed ID: 27106082
[TBL] [Abstract][Full Text] [Related]
16. Anti-septic effects of fisetin in vitro and in vivo.
Yoo H; Ku SK; Han MS; Kim KM; Bae JS
Inflammation; 2014 Oct; 37(5):1560-74. PubMed ID: 24706001
[TBL] [Abstract][Full Text] [Related]
17. High-mobility group box-1 isoforms as potential therapeutic targets in sepsis.
Parrish W; Ulloa L
Methods Mol Biol; 2007; 361():145-62. PubMed ID: 17172710
[TBL] [Abstract][Full Text] [Related]
18. HMGB1 as a potential therapeutic target.
Wang H; Li W; Goldstein R; Tracey KJ; Sama AE
Novartis Found Symp; 2007; 280():73-85; discussion 85-91, 160-4. PubMed ID: 17380789
[TBL] [Abstract][Full Text] [Related]
19. Targeting high mobility group box 1 as a late-acting mediator of inflammation.
Czura CJ; Tracey KJ
Crit Care Med; 2003 Jan; 31(1 Suppl):S46-50. PubMed ID: 12544976
[TBL] [Abstract][Full Text] [Related]
20. Anti-septic effects of pellitorine in HMGB1-induced inflammatory responses in vitro and in vivo.
Ku SK; Lee IC; Kim JA; Bae JS
Inflammation; 2014 Apr; 37(2):338-48. PubMed ID: 24077682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
